Medicines labeled for the same conditions
Alternatives to bevacizumab
12 other medicines are given the same way (intravenous) and in the same FDA class as bevacizumab or labeled mainly for the same use (colorectal cancer); 2 are in its class, vascular endothelial growth factor inhibitors: bevacizumab-maly and aflibercept; the others include 2 programmed death receptor-1 blocking antibodies, 2 epidermal growth factor receptor antagonists and 1 platinum-based drug (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as bevacizumab?
Colorectal cancer lists all 23 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Bevacizumabvascular endothelial growth factor inhibitor | this medicine | none listed | n/a | No | No current entry |
| Bevacizumab-malyvascular endothelial growth factor inhibitor · same class | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
| Afliberceptvascular endothelial growth factor inhibitor · same class | Colorectal cancer | none listed | n/a | No | No current entry |
| Oxaliplatinplatinum-based drug | Colorectal cancer | 17 labelers | n/a | Yes | A presentation being discontinued |
| Fluorouracilnucleoside metabolic inhibitor | Colorectal cancer | 12 labelers | n/a | Yes | No current entry |
| Irinotecantopoisomerase inhibitor | Colorectal cancer | 12 labelers | n/a | Yes | A presentation being discontinued |
| Levoleucovorinfolate analog | Colorectal cancer | 8 labelers | n/a | No | No current entry |
| Nivolumabprogrammed death receptor-1 blocking antibody | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
| Ipilimumabctla-4-directed blocking antibody | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
| Ramucirumabvascular endothelial growth factor receptor 2 antagonist | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
| Cetuximabepidermal growth factor receptor antagonist | Colorectal cancer | none listed | n/a | Yes | No current entry |
| Panitumumabepidermal growth factor receptor antagonist | Colorectal cancer | none listed | n/a | Yes | No current entry |
| Pembrolizumabprogrammed death receptor-1 blocking antibody | Lung cancer, Colorectal cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Bevacizumab: the full record
- label, generics, price, shortages, recalls